Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy

Neale Hanke, Darya Alizadeh, Emmanuel Katsanis, Nicolas Larmonier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Universally viewed as the sentinels and messengers of the immune system and traditionally referred to as professional antigen-presenting cells, dendritic cells (DCs) play a fundamental role in antitumor immunity. DCs are uniquely equipped with the ability to acquire, process, and present to T lymphocytes tumor-derived antigens. They can drive the differentiation of naïve T cells into activated tumor-specific effector lymphocytes. DCs also dictate the type and regulate the strength and duration of T-cell responses. In addition, they contribute to natural killer and natural killer T-cell antitumoral function and to B-cell-mediated immunity. Besides this cardinal role as orchestrators of innate and adaptive immune responses, many studies have provided evidence that DCs can also function as direct cytotoxic effectors against tumors. This less conventional aspect of DC function has, however, raised controversy as it relates to the origin of these cells and the induction, regulation, and mechanisms underlying their tumoricidal activity. The possible impact of the cytotoxic function of DCs on their capability to present antigens also has been the focus of intensive research. This review examines these questions and discusses the biological significance of this nontraditional property and possible strategies to exploit the killing potential of DCs in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)1-21
Number of pages21
JournalCritical Reviews in Immunology
Volume33
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Immunotherapy
Dendritic Cells
Neoplasms
T-Lymphocytes
Natural Killer T-Cells
Adaptive Immunity
Neoplasm Antigens
Antigen-Presenting Cells
Innate Immunity
Cellular Immunity
Immune System
Immunity
B-Lymphocytes
Lymphocytes
Antigens
Research

Keywords

  • Cytotoxic dendritic cells
  • Dendritic cell-based cancer vaccines
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology

Cite this

Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. / Hanke, Neale; Alizadeh, Darya; Katsanis, Emmanuel; Larmonier, Nicolas.

In: Critical Reviews in Immunology, Vol. 33, No. 1, 2013, p. 1-21.

Research output: Contribution to journalArticle

@article{078496a6daf646939fba02b1892f8385,
title = "Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy",
abstract = "Universally viewed as the sentinels and messengers of the immune system and traditionally referred to as professional antigen-presenting cells, dendritic cells (DCs) play a fundamental role in antitumor immunity. DCs are uniquely equipped with the ability to acquire, process, and present to T lymphocytes tumor-derived antigens. They can drive the differentiation of na{\"i}ve T cells into activated tumor-specific effector lymphocytes. DCs also dictate the type and regulate the strength and duration of T-cell responses. In addition, they contribute to natural killer and natural killer T-cell antitumoral function and to B-cell-mediated immunity. Besides this cardinal role as orchestrators of innate and adaptive immune responses, many studies have provided evidence that DCs can also function as direct cytotoxic effectors against tumors. This less conventional aspect of DC function has, however, raised controversy as it relates to the origin of these cells and the induction, regulation, and mechanisms underlying their tumoricidal activity. The possible impact of the cytotoxic function of DCs on their capability to present antigens also has been the focus of intensive research. This review examines these questions and discusses the biological significance of this nontraditional property and possible strategies to exploit the killing potential of DCs in cancer immunotherapy.",
keywords = "Cytotoxic dendritic cells, Dendritic cell-based cancer vaccines, Tumor immunity",
author = "Neale Hanke and Darya Alizadeh and Emmanuel Katsanis and Nicolas Larmonier",
year = "2013",
doi = "10.1615/CritRevImmunol.2013006679",
language = "English (US)",
volume = "33",
pages = "1--21",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "1",

}

TY - JOUR

T1 - Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy

AU - Hanke, Neale

AU - Alizadeh, Darya

AU - Katsanis, Emmanuel

AU - Larmonier, Nicolas

PY - 2013

Y1 - 2013

N2 - Universally viewed as the sentinels and messengers of the immune system and traditionally referred to as professional antigen-presenting cells, dendritic cells (DCs) play a fundamental role in antitumor immunity. DCs are uniquely equipped with the ability to acquire, process, and present to T lymphocytes tumor-derived antigens. They can drive the differentiation of naïve T cells into activated tumor-specific effector lymphocytes. DCs also dictate the type and regulate the strength and duration of T-cell responses. In addition, they contribute to natural killer and natural killer T-cell antitumoral function and to B-cell-mediated immunity. Besides this cardinal role as orchestrators of innate and adaptive immune responses, many studies have provided evidence that DCs can also function as direct cytotoxic effectors against tumors. This less conventional aspect of DC function has, however, raised controversy as it relates to the origin of these cells and the induction, regulation, and mechanisms underlying their tumoricidal activity. The possible impact of the cytotoxic function of DCs on their capability to present antigens also has been the focus of intensive research. This review examines these questions and discusses the biological significance of this nontraditional property and possible strategies to exploit the killing potential of DCs in cancer immunotherapy.

AB - Universally viewed as the sentinels and messengers of the immune system and traditionally referred to as professional antigen-presenting cells, dendritic cells (DCs) play a fundamental role in antitumor immunity. DCs are uniquely equipped with the ability to acquire, process, and present to T lymphocytes tumor-derived antigens. They can drive the differentiation of naïve T cells into activated tumor-specific effector lymphocytes. DCs also dictate the type and regulate the strength and duration of T-cell responses. In addition, they contribute to natural killer and natural killer T-cell antitumoral function and to B-cell-mediated immunity. Besides this cardinal role as orchestrators of innate and adaptive immune responses, many studies have provided evidence that DCs can also function as direct cytotoxic effectors against tumors. This less conventional aspect of DC function has, however, raised controversy as it relates to the origin of these cells and the induction, regulation, and mechanisms underlying their tumoricidal activity. The possible impact of the cytotoxic function of DCs on their capability to present antigens also has been the focus of intensive research. This review examines these questions and discusses the biological significance of this nontraditional property and possible strategies to exploit the killing potential of DCs in cancer immunotherapy.

KW - Cytotoxic dendritic cells

KW - Dendritic cell-based cancer vaccines

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84875083427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875083427&partnerID=8YFLogxK

U2 - 10.1615/CritRevImmunol.2013006679

DO - 10.1615/CritRevImmunol.2013006679

M3 - Article

C2 - 23510023

AN - SCOPUS:84875083427

VL - 33

SP - 1

EP - 21

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 1

ER -